nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.03.2009 | Original Article

Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study

verfasst von: Andrew M. Scott, Dishan H. Gunawardana, Joseph Wong, Ian Kirkwood, Rodney J. Hicks, Ivan Ho Shon, Jayne E. Ramshaw, Peter Robins

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Positron emission tomography (PET) was evaluated in low-grade non-Hodgkin lymphoma (NHL) to determine its impact on staging and management and to compare PET and gallium scans.

Methods

PET resulted in management plan changes in 74 patients with untreated low-grade NHL stages I to III. Patient outcomes to 12 months were documented.

Results

PET identified additional lesions in 50% of patients, led to a change in stage in 32%, and had a significant impact on management in 34%. Inferior progression-free survival was noted in patients with additional lesions detected by PET (p=0.001) and in the 28% of patients upstaged by PET to stage III or IV (p=0.024). In a subset of 16 patients undergoing both PET and gallium scans, PET was found to be superior.

Conclusion

PET has a major role in the management of low-grade NHL in addition to its proven role in aggressive lymphoma.

MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14:1282–90.

Paryani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS. Analysis of non-Hodgkin’s lymphomas with nodular and favorable histologies, stages I and II. Cancer 1983;52:2300–7.PubMedCrossRef

Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC. Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994;69:1088–93.PubMed

Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984;10:489–97.PubMed

McLaughlin P, Fuller LM, Velasquez WS, Butler JJ, Hagemeister FB, Sullivan-Halley JA, et al. Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 1987;5:867–74.PubMed

Murtha AD, Rupnow BA, Hansosn J, Knox SJ, Hoppe R. Long-term follow-up of patients with stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys 2001;49:3–15.PubMed

Jacobs JP, Murray KJ, Schultz CJ, Wilson JF, Goswitz MS, Stevens CW, et al. Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results. J Clin Oncol 1993;11:233–8.PubMed

Schöder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME, et al. Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001;42:1139–43.PubMed

Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol 2000;11:1273–9.PubMedCrossRef

10.

Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175–83.PubMedCrossRef

11.

Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (¹⁸F- FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 2001;12:825–30.PubMedCrossRef

12.

Longo DL, Schilsky RL, Blei L, Cano R, Johnston GS, Young RC. Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin’s lymphoma. Am J Med 1980;68:695–700.PubMedCrossRef

13.

Ben-Haim S, Bar-Shalom R, Israel O, Haim N, Epelbaum R, Ben-Shachar M, et al. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1996;14:1936–42.PubMed

14.

Bar-Shalom R, Yefremov N, Haim N, Dann EJ, Epelbaum R, Keidar Z, et al. Camera-based FDG PET and ⁶⁷Ga SPECT in evaluation of lymphoma: comparative study. Radiology 2003;227:353–60.PubMedCrossRef

15.

Wirth A, Seymour JF, Hicks RJ, Ware R, Prince M, MacManus MP, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma. Am J Med 2002;112:262–8.PubMedCrossRef

16.

Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64:336–40.PubMedCrossRef

17.

Blum RH, Seymour JF, Wirth A, MacManus M, Hicks RJ. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin’s lymphoma. Clin Lymphoma 2003;4:43–9.PubMedCrossRef

18.

Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-PET with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110:652–9.PubMedCrossRef

19.

Hoffmann M, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D- glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185–9.PubMedCrossRef

20.

Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2005;23:4643–51.PubMedCrossRef

Titel: Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study
verfasst von: Andrew M. Scott
Dishan H. Gunawardana
Joseph Wong
Ian Kirkwood
Rodney J. Hicks
Ivan Ho Shon
Jayne E. Ramshaw
Peter Robins
Publikationsdatum: 01.03.2009
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0958-z

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study

Monoamine transporter availability in Parkinson’s disease patients with or without depression

Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?

Is the lung scan alive and well? Facts and controversies in defining the role of lung scintigraphy for the diagnosis of pulmonary embolism in the era of MDCT

Image-derived input functions for PET brain studies

Syllabus for postgraduate specialisation in Nuclear Medicine